(51) have demonstrated a newly screened cyclic peptide C8, which can be removed in a shorter period of time to reverse the irAEs due to its reasonable half-life, could work as a blocker for PD-1 and reactivate CD8+ T cells to treat cancers. The gene discussed is CD8A; the disease is cancer.